Similar articles

• A prospective controlled study of neurodevelopment in HIV-uninfected children exposed to combination antiretroviral drugs in pregnancy.

  Alimenti A, Forbes JC, Oberlander TF, Money DM, Grunau RE, Papsdorf MP, Maan E, Cole LJ, Burdge DR. Alimenti A, et al. Pediatrics. 2006 Oct;118(4):e1139-45. doi: 10.1542/peds.2006-0525. Epub 2006 Aug 28. Pediatrics. 2006. PMID: 16940166
• The impact of ongoing illicit drug use on methadone adherence in illicit drug users receiving treatment for HIV in a directly observed therapy program.

  Raffa JD, Grebely J, Tossonian H, Wong T, Viljoen M, Khara M, Mead A, McLean M, Duncan F, Petkau AJ, DeVlaming S, Conway B. Raffa JD, et al. Drug Alcohol Depend. 2007 Jul 10;89(2-3):306-9. doi: 10.1016/j.drugalcdep.2007.02.007. Epub 2007 Mar 23. Drug Alcohol Depend. 2007. PMID: 17383117
• The challenging interactions between antiretroviral agents and addiction drugs.

  Khalsa J, Genser S, Vocci F, Francis H, Bean P. Khalsa J, et al. Am Clin Lab. 2002 Apr;21(3):10-3. Am Clin Lab. 2002. PMID: 12038078 Review. No abstract available.
• The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study.

  Roux P, Carrieri MP, Villes V, Dellamonica P, Poizot-Martin I, Ravaux I, Spire B; MANIF2000 cohort study group. Roux P, et al. Addiction. 2008 Nov;103(11):1828-36. doi: 10.1111/j.1360-0443.2008.02323.x. Epub 2008 Sep 4. Addiction. 2008. PMID: 18778390
• Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST).

  Spire B, Lucas GM, Carrieri MP. Spire B, et al. Int J Drug Policy. 2007 Aug;18(4):262-70. doi: 10.1016/j.drugpo.2006.12.014. Epub 2007 Jan 26. Int J Drug Policy. 2007. PMID: 17689374 Review.